慢性阻塞性肺疾病患者治疗后诱导痰细胞中 FKBP51 的增加。
Increased FKBP51 in induced sputum cells of chronic obstructive pulmonary disease patients after therapy.
机构信息
Department of Clinical Pharmacology, Medical University of Bialystok, Poland.
出版信息
Eur J Med Res. 2009 Dec 7;14 Suppl 4(Suppl 4):108-11. doi: 10.1186/2047-783x-14-s4-108.
OBJECTIVE
Immunophilin FKBP51 assists polypeptide folding, participates in glucocorticoid actions and may play a role in glucocorticoid resistance. FKBP51 is altered in patients with asthma, but its role in chronic obstructive pulmonary disease (COPD) characterized by dysregulation of several pro/antiinflammatory genes is less clear.
METHODS
We assessed changes in nuclear/cytosolic FKBP51 protein using SDS-PAGE/WB and FKBP51 mRNA by qRT-PCR in cells isolated from induced sputum of stable COPD patients treated with formoterol/budesonide or formoterol/budesonide/theo?phylline for 4 wk.
RESULTS
Expression of FKBP51 was higher in formoterol/ budesonide/theophylline-treated patients, compared with formoterol/budesonide group in both cytosolic and nuclear fractions by about 57% and 31%, respectively (P<0.001, P<0.01). FKBP51 mRNA was only slightly, but not significantly, higher in patients on formoterol/ budesonide/theophylline.
CONCLUSIONS
Increased FKBP51 in COPD patients treated with formoterol/ budesonide/theophylline may be important in altering signaling from corticosteroid receptors.
目的
免疫亲和素 FKBP51 协助多肽折叠，参与糖皮质激素作用，并可能在糖皮质激素抵抗中发挥作用。FKBP51 在哮喘患者中发生改变，但在以多个促炎/抗炎基因失调为特征的慢性阻塞性肺疾病（COPD）中的作用尚不清楚。
方法
我们使用 SDS-PAGE/WB 评估了稳定期 COPD 患者诱导痰细胞中核/胞质 FKBP51 蛋白的变化，并通过 qRT-PCR 评估 FKBP51 mRNA 的变化，这些患者接受福莫特罗/布地奈德或福莫特罗/布地奈德/茶碱治疗 4 周。
结果
与福莫特罗/布地奈德组相比，福莫特罗/布地奈德/茶碱组患者的 FKBP51 在胞质和核部分的表达分别增加了约 57%和 31%（P<0.001，P<0.01）。福莫特罗/布地奈德/茶碱组患者的 FKBP51 mRNA 只是略有升高，但无统计学意义。
结论
福莫特罗/布地奈德/茶碱治疗的 COPD 患者中 FKBP51 的增加可能在改变糖皮质激素受体信号转导方面很重要。
Zotero 插件